File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Lung cancer patient–derived organoid biobank for therapeutic screening

TitleLung cancer patient–derived organoid biobank for therapeutic screening
Authors
Issue Date2019
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
24th Medical Research Conference, Hong Kong, 19 January 2019. In Hong Kong Medical Journal, v. 25 n. Suppl.1, p. 24 How to Cite?
AbstractIntroduction: Precision medicine for lung cancer requires accurate diagnostic tests for individual patients. An in vitro model that allows high-throughput therapeutic screening but can also fully replicate the histopathological and molecular characteristics of the original tumour is indispensable. Methods: Resected tumour and the adjacent normal tissues from early-stage lung cancer patients were collected. Metastatic tumour cells from pleural effusion of advanced-stage lung cancer patients were also harvested and used for organoid culture establishment. Genomic analysis using whole-exome sequencing and histological examination were performed on those long-term cultured organoids. Drug sensitivity screening was performed on the tumour organoid cultures. Results: We established a lung cancer organoid biobank that comprehends normal, cancer, and pleural effusion metastases from patients with diversity of histological and genomic backgrounds. The morphology and genomic profiles of the established organoids were closely comparable with the original tissues. Highthroughput drug screening revealed the potential application of novel drugs. Conclusion: This newly established and well-characterised lung cancer biobank is a viable tool for lung cancer research as well as development of precision therapy
Persistent Identifierhttp://hdl.handle.net/10722/274152
ISSN
2017 Impact Factor: 1.226
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorKwok, HH-
dc.contributor.authorLee, CMN-
dc.contributor.authorDeng, J-
dc.contributor.authorIp, MSM-
dc.contributor.authorLam, CLD-
dc.date.accessioned2019-08-18T14:56:07Z-
dc.date.available2019-08-18T14:56:07Z-
dc.date.issued2019-
dc.identifier.citation24th Medical Research Conference, Hong Kong, 19 January 2019. In Hong Kong Medical Journal, v. 25 n. Suppl.1, p. 24-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/274152-
dc.description.abstractIntroduction: Precision medicine for lung cancer requires accurate diagnostic tests for individual patients. An in vitro model that allows high-throughput therapeutic screening but can also fully replicate the histopathological and molecular characteristics of the original tumour is indispensable. Methods: Resected tumour and the adjacent normal tissues from early-stage lung cancer patients were collected. Metastatic tumour cells from pleural effusion of advanced-stage lung cancer patients were also harvested and used for organoid culture establishment. Genomic analysis using whole-exome sequencing and histological examination were performed on those long-term cultured organoids. Drug sensitivity screening was performed on the tumour organoid cultures. Results: We established a lung cancer organoid biobank that comprehends normal, cancer, and pleural effusion metastases from patients with diversity of histological and genomic backgrounds. The morphology and genomic profiles of the established organoids were closely comparable with the original tissues. Highthroughput drug screening revealed the potential application of novel drugs. Conclusion: This newly established and well-characterised lung cancer biobank is a viable tool for lung cancer research as well as development of precision therapy-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleLung cancer patient–derived organoid biobank for therapeutic screening-
dc.typeConference_Paper-
dc.identifier.emailKwok, HH: kwokh@hku.hk-
dc.identifier.emailLee, CMN: nerissal@hku.hk-
dc.identifier.emailDeng, J: jdengmo@hku.hk-
dc.identifier.emailIp, MSM: msmip@hku.hk-
dc.identifier.emailLam, CLD: dcllam@hku.hk-
dc.identifier.authorityIp, MSM=rp00347-
dc.identifier.authorityLam, CLD=rp01345-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros301610-
dc.identifier.volume25-
dc.identifier.issueSuppl.1-
dc.identifier.spage24-
dc.identifier.epage24-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats